Table 1 Clinical data summary for SMC and TCGA
From: Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures
SMC | TCGA | Statistical significance | |
|---|---|---|---|
Subjects (n) | 187 | 1,116 | |
Patient age (yr) | 39.3 ± 8.5 | 58.3 ± 13.2 | p < 2.2e-16 |
Tumor purity (%) | 71 ± 17.8 | 77.7 ± 10.7 | p = 0.0005 |
Menopausal status (n(%)) | |||
Pre-menopausal | 165 (88.2%) | 232 (20.8%) | p = 1.12e-76 |
Post-menopausal | 19 (10.2%) | 715 (64.1%) | p = 2.4e-68 |
Peri-menopausal | 41 (3.7%) | ||
N/A | 128 (11.5%) | ||
Clinical subtype (n(%)) | |||
ER+ | 103 (55.1%) | 480 (43.0%) | p = 0.04 |
ER+/HER2+ | 27 (14.4%) | 116 (10.4%) | |
HER2+ | 15 (8%) | 32 (2.9%) | p = 0.07 |
TNBC | 37 (19.8%) | 121 (10.8%) | |
N/A | 5 (2.7%) | 367 (32.9%) | |
TNM stage (n(%)) | |||
I | 27 (14.4%) | 177 (15.9%) | |
II | 101 (54%) | 605 (54.2%) | |
III | 58 (31%) | 237 (21.2%) | |
V | 1 (0.5%) | 18 (1.6%) | |
N/A | 79 (7.1%) | ||
Histology subtype (n(%)) | |||
Lobular carcinoma | 7 (3.7%) | 193 (17.3%) | p = 2.9e-08 |
Ductal Carcinoma | 172 (92.0%) | 830 (74.4%) | p = 2.9e-08 |
Others | 8 (4.3%) | 37 (3.3%) | |
N/A | 56 (5.0%) | ||
Race (n(%)) | |||
Asian | 187 (100%) | 57 (5.1%) | p = 2.53e-193 |
Black | 158 (14.2%) | ||
White | 745 (66.8%) | ||
N/A | 156 (14%) |
